EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

The novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications

Mario García-Gómez, Clara Fernández-Cordón, José Carlos González-Gutiérrez, Ana Serrador, Alberto Campo, Carlos Cortés Villar, Sara Blasco Turrión, Cristhian Aristizábal, Julio Peral Oliveira, Alexander Stepanenko, Mikel González Arribas, Luca Scorpiglione und 4 weitere

Revista Española de Cardiología (English Edition) · 2025

DOI: 10.1016/j.rec.2024.09.006 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Revista Española de Cardiología (English Edition), 2025. Verfasst von Mario García-Gómez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain. Electronic address: https://t…. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Tricuspid Valve, Pulmonary Valve, Mitral Valve. Die Arbeit nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND OBJECTIVES: Myval technology represents the first balloon-expandable alternative since the Edwards system became commercially available. Despite certain controversies, its use has rapidly expanded. We aimed to gather all the available literature regarding its indications and outcomes. METHODS: A comprehensive search of articles published between December 2016 and May 2024 was conducted using BioMedCentral, Google Scholar, and PubMed to evaluate the main outcomes of Myval for native aortic stenosis (AS) (meta-analysis) and off-label uses (systematic review). RESULTS: A total of 151 studies were identified, and 74 were included in the analysis, covering aortic (n=51), mitral (n=9), tricuspid (n=6), and pulmonary (n=8) valve positions. A meta-analysis of studies on native AS demonstrated that Myval is safe and effective, with a 30-day mortality rate of 1.3%, good hemodynamic performance, low rates of pacemaker implantation (8.8%), and ≥ moderate paravalvular regurgitation (1.3%). Compared with other contemporary devices, Myval was competitive and associated with lower rates of pacemaker implantation. In a systematic review of off-label indications, Myval was also found to be safe and effective. In bicuspid AS, pure regurgitation, and aortic valve-in-valve procedures, success rates were 100%, 92%, and 100%, respectively, with pacemaker rates of 9.9%, 22.2%, and 3%, respectively. For mitral valve-in-valve/in-ring procedures, the success rate was 96.9%, while in tricuspid and pulmonary positions, small case series reported 100% success rates for both, with minimal procedural complications. CONCLUSIONS: Myval technology is safe and effective for the treatment of native valvular disease and dysfunctional prostheses or rings in all heart valve positions, although larger scale studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve ProsthesisTricuspid ValvePulmonary ValveMitral ValveAortic ValveHeart Valve DiseasesHeart Valve Prosthesis ImplantationHumansProsthesis Design

Stichwörter der Autor:innen

Aortic RegurgitationAortic stenosisEstenosis aórticaInsuficiencia aórticaMyvalMyval OctacorValve-in-ringValve-in-valveValvular heart diseaseValvulopatías

Autor:innen und Institutionen

  • Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain. Electronic address: https://twitter.com/@mariogago13.
  • Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
  • Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. Electro…

Zitieren

APA

García-Gómez, M., Fernández-Cordón, C., González-Gutiérrez, J. C., Serrador, A., Campo, A., Cortés Villar, C., Blasco Turrión, S., Aristizábal, C., Peral Oliveira, J., Stepanenko, A., González Arribas, M., Scorpiglione, L., Jain, A., Carnicero Martínez, D., San Román, J. A., & Amat-Santos, I. J. (2025). The novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2024.09.006

Vancouver

García-Gómez M, Fernández-Cordón C, González-Gutiérrez JC, Serrador A, Campo A, Cortés Villar C, et al. The novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications. Revista Española de Cardiología (English Edition). 2025. doi:10.1016/j.rec.2024.09.006

BibTeX
@article{GarcaGmez2025,
  author = {García-Gómez, Mario and Fernández-Cordón, Clara and González-Gutiérrez, José Carlos and Serrador, Ana and Campo, Alberto and Cortés Villar, Carlos and Blasco Turrión, Sara and Aristizábal, Cristhian and Peral Oliveira, Julio and Stepanenko, Alexander and González Arribas, Mikel and Scorpiglione, Luca and Jain, Akash and Carnicero Martínez, David and San Román, J Alberto and Amat-Santos, Ignacio J},
  title = {The novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications},
  journal = {Revista Española de Cardiología (English Edition)},
  year = {2025},
  doi = {10.1016/j.rec.2024.09.006}
}
Kostenlos starten →